Skip to main content
RUBICON RESEARCH LIMITED logo

RUBICON RESEARCH LIMITED — Investor Relations & Filings

Ticker · RUBICON ISIN · INE506V01022 LEI · 335800GME6PCQIKP8T34 BSE.NS Manufacturing
Open in API
Filings indexed 112 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS RUBICON

About RUBICON RESEARCH LIMITED

https://www.rubicon.co.in/

Rubicon Research Limited is a specialty organization focused on formulation development and the commercialization of value-added products. The company leverages proprietary drug delivery technology platforms to develop complex oral solids, liquids, topicals, and sterile dosage forms. Its core business activities encompass contract research and manufacturing services alongside the development of a diverse portfolio of Abbreviated New Drug Applications. The firm operates advanced research and development centers and manufacturing facilities that comply with stringent international regulatory standards. Rubicon Research emphasizes innovation in life cycle management and the enhancement of existing molecules to improve patient compliance and therapeutic outcomes. Its operations provide end-to-end solutions from initial concept and formulation design to commercial-scale production, serving global markets with a focus on high-quality, technology-driven solutions.

Recent filings

Filing Released Lang Actions
Updates
Share Issue/Capital Change Classification · 95% confidence The document is a formal stock exchange filing under SEBI Listing Regulations disclosing the allotment of fully paid-up equity shares pursuant to employee stock option exercise and the resultant increase in issued and paid-up share capital. This is a direct announcement of a share issue/capital change rather than a broader report or meeting material. Therefore, it fits the Share Issue/Capital Change category (SHA).
2026-05-29 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (SEBI Listing Regulations)
Share Issue/Capital Change Classification · 91% confidence The document is an exchange intimation under SEBI Listing Regulations notifying the allotment of 290,626 equity shares upon exercise of employee stock options and the consequent increase in paid-up share capital. This is a direct announcement of a share issuance/capital change, matching the definition of Share Issue/Capital Change (Code: SHA).
2026-05-29 English
Annual Secretarial Compliance Report for year ended March 31, 2026
Regulatory Filings Classification · 87% confidence The document is titled “Annual Secretarial Compliance Report” for the year ended March 31, 2026 and is filed under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a statutory compliance certificate/report prepared by a practicing company secretary and submitted to stock exchanges. This type of compliance filing does not contain the company’s financial statements or governance policy narratives in a format typical of an Annual Report (10-K), nor is it an ESG/Social Responsibility Report or Board change notice. It is a routine regulatory filing/certification, which maps to our “Regulatory Filings” category (RNS).
2026-05-29 English
Statement on Deviation/variation of Funds and further extension of timeline for utilization of IPO Proceeds.
Regulatory Filings Classification · 97% confidence The document is a regulatory disclosure to stock exchanges under SEBI Listing Regulations (Regulation 30 & 32) regarding deviation/variation in IPO proceeds utilisation and an extension of timeline for deployment. It is not an annual or interim report, not a management discussion, and contains no financial statements itself; rather it is a compliance announcement. This aligns with the generic “Regulatory Filings” category.
2026-05-29 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 85% confidence The document is a statutory disclosure submitted to BSE and NSE under SEBI Listing Regulations (Regulation 30 and 32) providing a statement on deviation/variation of IPO proceeds utilisation and an extension of the timeline. It is a compliance/regulatory announcement rather than a standalone financial report, dividend notice, share issuance, or financing transaction. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-29 English
Board recommends dividend for year ended March 31, 2026
Audit Report / Information Classification · 90% confidence The document is a formal SEBI Listing Regulations filing conveying the Board’s approval of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the Independent Auditor’s Report (unmodified opinion) by Deloitte. It is not a full Annual Report, earnings highlights, or mere announcement of publication, but rather the standalone audit report/information on the financial results. Therefore, it best fits the Audit Report / Information category. FY 2026
2026-05-29 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.